SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Oct 9, 2018
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Oct. 9, 2018 · CIK: 0000921114 · Accession: 0001144204-18-052985
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226959
Letter
Re: AmpliPhi Biosciences Corporation
October 9, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (Registration No. 333-226959), as amended - Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), hereby concurs in the request by AmpliPhi Biosciences Corporation (the “Registrant”) that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter, on October 10, 2018, or at such later time as the Registrant or its outside counsel, Cooley LLP, may orally request by telephone call to the staff that such Registration Statement be declared effective. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
Wainwright hereby represents that it is acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
October 9, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: AmpliPhi Biosciences Corporation
Registration Statement on Form S-1 (Registration
No. 333-226959), as amended - Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”),
as underwriter for the referenced offering, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities
Act”), hereby concurs in the request by AmpliPhi Biosciences Corporation (the “Registrant”) that the
effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated
to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter, on October 10, 2018, or at such later time as the Registrant
or its outside counsel, Cooley LLP, may orally request by telephone call to the staff that such Registration Statement be declared
effective. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Pursuant to Rule 460 under the Securities
Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited
to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to
be reasonable to secure adequate distribution of the preliminary prospectus.
Wainwright hereby represents that it is
acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act
of 1934, as amended, in connection with the above proposed offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:
/s/ Mark W. Viklund
Name: Mark W. Viklund
Title: Chief Executive Officer
430
Park Avenue | New York, New York 10022 | 212.356.0500
Security services
provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC